Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Agulnik, M.D.
Northwestern University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sarcoma Oncology Center
Santa Monica, California, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- University of Iowa
Iowa City, Iowa, United States
- University of Minnesota Medical Center-Fairview
Minneapolis, Minnesota, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Washington University-St. Louis
St Louis, Missouri, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Jun 2014
- Primary completion
- 14 Oct 2019
- Completion
- 12 Oct 2021
- Last update posted
- 25 Apr 2022
- Registered enrollment
- 31
- Registry id
- NCT02048722
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.